酪酸梭菌活菌散联合乳果糖、饮食疗法治疗儿童功能性便秘的效果分析

Effect of clostridium butyricum powder combined with lactulose and diet therapy on functional constipation in children

摘要:

目的 探讨酪酸梭菌活菌散+乳果糖+饮食疗法方案治疗儿童功能性便秘的临床效果。方法 选取徐州市儿童医院2018年4月—2019年6月门诊接诊的80例功能性便秘患儿为研究对象，按随机数字表法分为两组，对照组（40例）行乳果糖+饮食疗法等常规治疗，观察组（40例）在对照组基础上再加用酪酸梭菌活菌散进行治疗。采用放射免疫法测定P物质水平，采用酶联免疫吸附法测定生长抑素水平；比较两组患儿便质干硬、排便疼痛、排便频率< 1次/d的变化情况；比较两组患儿排便恢复正常时间、住院时间、总有效率及相关不良反应发生情况。结果 治疗4周后，观察组血清P物质水平高于对照组（P <0.05），生长抑素水平低于对照组（P <0.05）；观察组治疗后便质干硬、排便疼痛及排便频率< 1次/d发生率低于对照组（P <0.05）；观察组排便恢复正常时间、住院时间短于对照组（P <0.05），治疗总有效率高于对照组（P <0.05）。不良反应总发生率与对照组比较，差异无统计学意义（P >0.05）。结论 酪酸梭菌活菌散+乳果糖+饮食疗法方案治疗儿童功能性便秘，可改善患儿的胃肠激素水平和临床症状，提高治疗总有效率，且不会引起严重不良反应，具有安全性。

Abstract:

Objective To evaluate the clinical effect of clostridium butyricum powder + lactulose + Diet therapy on functional constipation (FC) in children.Methods The 80 children with FC received in our hospital from April 2018 to June 2019 were divided into two groups. The Control Group (40 cases) received routine treatment such as lactulose plus Diet therapy, while the observation group (40 cases) was treated with clostridium butyricum powder. The level of substance P was determined by radioimmunoassay, and the level of somatostatin was determined by enzyme-linked immunosorbent assay; the rate of dry and hard stools, the rate of defecation pain, and the rate of defecation frequency < 1 time/d were observed; the defecation rate of the children was observed. Time to return to normal, length of hospital stay, total curative effect, and occurrence of related adverse reactions were recorded.Results After treatment, the serum SP level in the observation group was higher than that in the control group (P < 0.05), and the SS level was lower than that in the control group (P < 0.05); the rate of dry and hard stool, the rate of painful defecation, and the rate of defecation frequency less than 1 time/d were lower than that in the control group (P < 0.05); the defecation recovery was normal and the days of hospitalization were shorter than that in the control group (P < 0.05), and the total efficiency of treatment was higher than that in the control group (P < 0.05). There was no statistically significant difference in the total incidence of adverse reactions compared with the control group (P > 0.05).Conclusion Lactulose, diet therapy, and clostridium butyricum powder were used in FC clinical treatment, can improve the clinical symptoms and signs of children, improve the overall efficacy, and will not cause serious adverse reactions with ideal safety.